{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:07:51Z","timestamp":1791328071667,"version":"4.3.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although immunosuppression has long been recognized in Hodgkin lymphoma (HL), the underlying basis for the lack of an effective immune response against the tumor remains unclear. The aim was to test our hypothesis that regulatory T cells dominate involved lymph nodes. The approach was to assay CD4+ T-cell function in HL-infiltrating lymphocytes (HLILs) and paired peripheral blood mononuclear cells (PBMCs) of 24 patients. Strikingly, unlike PBMCs, HLILs were anergic to stimulation with mitogen, primary, or recall antigens, mounting no proliferative responses and only rare T-helper 1 (Th1) or Th2 cytokine responses. Mixing paired HLILs and PBMCs showed the anergic effect was dominant and suppressed PBMC responses. Furthermore, flow cytometry demonstrated that HLILs contained large populations of both interleukin-10 (IL-10)\u2013secreting T-regulatory 1 (Tr1) and CD4+CD25+ regulatory T cells. We found evidence for 3 mechanisms of action implicated in the suppressive functions of regulatory T cells: the inhibition of PBMCs by HLILs was ameliorated by neutralizing IL-10, by preventing cell-to-cell contact, and by blocking anti\u2013cytotoxic T lymphocyte\u2013associated antigen 4 (anti\u2013CTLA-4). Thus, HLILs are highly enriched for regulatory T cells, which induce a profoundly immunosuppressive environment and so provide an explanation for the ineffective immune clearance of Hodgkin-Reed Sternberg cells.<\/jats:p>","DOI":"10.1182\/blood-2003-07-2594","type":"journal-article","created":{"date-parts":[[2003,11,11]],"date-time":"2003-11-11T01:13:36Z","timestamp":1068513216000},"page":"1755-1762","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":415,"title":["Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma"],"prefix":"10.1182","volume":"103","author":[{"given":"Neil A.","family":"Marshall","sequence":"first","affiliation":[{"name":"From the Department of Medicine and Therapeutics, Department of Haematology, and Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsey E.","family":"Christie","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Therapeutics, Department of Haematology, and Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R.","family":"Munro","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Therapeutics, Department of Haematology, and Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Culligan","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Therapeutics, Department of Haematology, and Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Johnston","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Therapeutics, Department of Haematology, and Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Barker","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Therapeutics, Department of Haematology, and Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Vickers","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Therapeutics, Department of Haematology, and Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222125629000_REF1","doi-asserted-by":"crossref","unstructured":"Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99: 4283-4297.","DOI":"10.1182\/blood-2002-01-0099"},{"key":"2020021222125629000_REF2","unstructured":"Reed DM. On pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10: 133-196."},{"key":"2020021222125629000_REF3","doi-asserted-by":"crossref","unstructured":"Green I, Corse PF. A study of skin homografting in patients with lymphomas. Blood. 1959;14: 235-245.","DOI":"10.1182\/blood.V14.3.235.235"},{"key":"2020021222125629000_REF4","unstructured":"Miller DG, Lizardo JG, Snyderman RK. Homologous and heterologous skin tranplantation in patients with lymphomatous disease. J Natl Cancer Inst. 1961;26: 569-579."},{"key":"2020021222125629000_REF5","doi-asserted-by":"crossref","unstructured":"Baglin TP, Joysey VC, Horsford J, Johnson RT, Broadbent V, Marcus RE. Transfusion-associated graft-versus-host disease in patients with Hodgkin's disease and T cell lymphoma. Transfus Med. 1992;2: 195-199.","DOI":"10.1111\/j.1365-3148.1992.tb00155.x"},{"key":"2020021222125629000_REF6","doi-asserted-by":"crossref","unstructured":"Levy R, Kaplan HS. Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med. 1974;290: 181-186.","DOI":"10.1056\/NEJM197401242900402"},{"key":"2020021222125629000_REF7","doi-asserted-by":"crossref","unstructured":"Hellinger SM, Herzig GP. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes. J Clin Invest. 1978;61: 1620-1627.","DOI":"10.1172\/JCI109082"},{"key":"2020021222125629000_REF8","doi-asserted-by":"crossref","unstructured":"Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone, I: definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136: 2348-2357.","DOI":"10.4049\/jimmunol.136.7.2348"},{"key":"2020021222125629000_REF9","doi-asserted-by":"crossref","unstructured":"Roncarolo M, Levings MK. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol. 2000;12: 676-683.","DOI":"10.1016\/S0952-7915(00)00162-X"},{"key":"2020021222125629000_REF10","doi-asserted-by":"crossref","unstructured":"Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol. 2000;18: 423-449.","DOI":"10.1146\/annurev.immunol.18.1.423"},{"key":"2020021222125629000_REF11","doi-asserted-by":"crossref","unstructured":"Shevach EM. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3: 199-210.","DOI":"10.1038\/nri1027"},{"key":"2020021222125629000_REF12","doi-asserted-by":"crossref","unstructured":"Levings MK, Roncarolo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol. 2000;106: S109-S112.","DOI":"10.1067\/mai.2000.106635"},{"key":"2020021222125629000_REF13","doi-asserted-by":"crossref","unstructured":"Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182: 207-214.","DOI":"10.1034\/j.1600-065X.2001.1820117.x"},{"key":"2020021222125629000_REF14","doi-asserted-by":"crossref","unstructured":"Piccirillo CA, Letterio JJ, Thornton AM, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med. 2002;196: 237-246.","DOI":"10.1084\/jem.20020590"},{"key":"2020021222125629000_REF15","doi-asserted-by":"crossref","unstructured":"McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol. 2002;110: 693-702.","DOI":"10.1067\/mai.2002.129339"},{"key":"2020021222125629000_REF16","doi-asserted-by":"crossref","unstructured":"Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000;10: 345-350.","DOI":"10.1006\/scbi.2000.0327"},{"key":"2020021222125629000_REF17","doi-asserted-by":"crossref","unstructured":"Dukers DF, Jaspars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J Pathol. 2000;190: 143-149.","DOI":"10.1002\/(SICI)1096-9896(200002)190:2<143::AID-PATH519>3.0.CO;2-5"},{"key":"2020021222125629000_REF18","doi-asserted-by":"crossref","unstructured":"Herbst H, Foss H-D, Samoi J, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood. 1996;87: 2918-2929.","DOI":"10.1182\/blood.V87.7.2918.bloodjournal8772918"},{"key":"2020021222125629000_REF19","doi-asserted-by":"crossref","unstructured":"Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97: 250-255.","DOI":"10.1182\/blood.V97.1.250"},{"key":"2020021222125629000_REF20","doi-asserted-by":"crossref","unstructured":"Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer. 2000;82: 1117-1121.","DOI":"10.1054\/bjoc.1999.1049"},{"key":"2020021222125629000_","unstructured":"Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129: 86-91."},{"key":"2020021222125629000_REF22","doi-asserted-by":"crossref","unstructured":"Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337: 320-322.","DOI":"10.1016\/0140-6736(91)90943-J"},{"key":"2020021222125629000_REF23","doi-asserted-by":"crossref","unstructured":"Frisan T, Sjoberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood. 1995;86: 1493-1501.","DOI":"10.1182\/blood.V86.4.1493.bloodjournal8641493"},{"key":"2020021222125629000_REF24","unstructured":"Chapman ALN, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumour site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 2001;61: 6219-6226."},{"key":"2020021222125629000_REF25","doi-asserted-by":"crossref","unstructured":"Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol. 2003;170: 6183-6189.","DOI":"10.4049\/jimmunol.170.12.6183"},{"key":"2020021222125629000_REF26","doi-asserted-by":"crossref","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339: 1506-1514.","DOI":"10.1056\/NEJM199811193392104"},{"key":"2020021222125629000_REF27","unstructured":"Plebanski M, Saunders M, Burtles SS, Crowe S, Hooper DC. Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms. Immunology. 1992;75: 86-91."},{"key":"2020021222125629000_REF28","doi-asserted-by":"crossref","unstructured":"Devereux G, Hall AM, Barker RN. Measurement of T-helper cytokines secreted by cord blood mononuclear cells in response to allergens. J Immunol Methods. 2000;234: 13-22.","DOI":"10.1016\/S0022-1759(99)00185-4"},{"key":"2020021222125629000_REF29","doi-asserted-by":"crossref","unstructured":"Hall AM, Ward FJ, Vickers MA, Stott LM, Urbaniak SJ, Barker RN. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood. 2002;100: 4529-4536.","DOI":"10.1182\/blood-2002-05-1383"},{"key":"2020021222125629000_REF30","unstructured":"Kim WU, Cho ML, Kim SI, et al. Divergent effect of cyclosporine on Th1\/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol. 2000;27: 324-331."},{"key":"2020021222125629000_REF31","doi-asserted-by":"crossref","unstructured":"Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192: 295-302.","DOI":"10.1084\/jem.192.2.295"},{"key":"2020021222125629000_REF32","doi-asserted-by":"crossref","unstructured":"Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001;38: 368-375.","DOI":"10.1046\/j.1365-2559.2001.01083.x"},{"key":"2020021222125629000_REF33","unstructured":"Tesch H, Gunther A, Abts H, et al. Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease. Am J Pathol. 1993;142: 1714-1720."},{"key":"2020021222125629000_REF34","unstructured":"Vandenborre K, Delabie J, Boogaerts MA, et al. Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease and in Hodgkin's disease. Am J Pathol. 1998;152: 963-973."},{"key":"2020021222125629000_REF35","doi-asserted-by":"crossref","unstructured":"Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev. 2001;182: 68-79.","DOI":"10.1034\/j.1600-065X.2001.1820105.x"},{"key":"2020021222125629000_REF36","doi-asserted-by":"crossref","unstructured":"Hsu SM, Lin J, Xie SS, Hsu PL, Rich S. Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol. 1993;24: 249-255.","DOI":"10.1016\/0046-8177(93)90034-E"},{"key":"2020021222125629000_REF37","doi-asserted-by":"crossref","unstructured":"Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol. 2002;32: 3267-3275.","DOI":"10.1002\/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1"},{"key":"2020021222125629000_REF38","doi-asserted-by":"crossref","unstructured":"Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3: 611-618.","DOI":"10.1038\/ni0702-611"},{"key":"2020021222125629000_REF39","doi-asserted-by":"crossref","unstructured":"Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreatic or breast adenocarcinoma. J Immunol. 2002;169: 2756-2761.","DOI":"10.4049\/jimmunol.169.5.2756"},{"key":"2020021222125629000_REF40","unstructured":"Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9: 606-612."},{"key":"2020021222125629000_REF41","doi-asserted-by":"crossref","unstructured":"Gottschalk S, Edwards OL, Huls MH, et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101: 1905-1912.","DOI":"10.1182\/blood-2002-05-1514"},{"key":"2020021222125629000_REF42","doi-asserted-by":"crossref","unstructured":"Culo F, Klapan I, Kolak T. The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors. Cancer Immunol Immunother. 1993;36: 115-122.","DOI":"10.1007\/BF01754411"},{"key":"2020021222125629000_REF43","unstructured":"Andrade-Mena CE. Cyclophosphamide-induced tumour regression of cyclophosphamide-resistant L5178Y lymphoma through suppressor cells elimination. Int J Tissue React. 1994;16: 95-103."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/5\/1755\/1695773\/zh800504001755.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/5\/1755\/1695773\/zh800504001755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T12:31:54Z","timestamp":1682598714000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/5\/1755\/18170\/Immunosuppressive-regulatory-T-cells-are-abundant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-07-2594","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}